New research from the lab of Thomas Gajewski, MD, PhD, showed that tumor cells can escape T cell killing during immunotherapy by using “clonal cooperation.” This work suggests that early treatment with immunotherapies may be more effective, before tumor cell heterogeneity emerges.
Several years ago, Linda Winkler and Scott McIntyre thought they had run out of options for treatment of relapsed lymphoma. An immunotherapy clinical trial changed the path for both patients. "Immunotherapy has been a game-changer for lymphoma patients," said their oncologist, Sonali Smith, MD.
UChicago Medicine opened a brand-new, state-of-the-art facility to manufacture novel cell therapies, such as CAR T-cells, which have shown great promise for the treatment of leukemia and lymphoma.